The Senate health committee advanced two of the Trump administration's public-health nominees on Thursday, sending Erica Schwartz's nomination to lead the CDC and Sean Kaufman's to run the Administration for Strategic Preparedness and Response to the full Senate. The votes fell almost entirely along party lines, 12-10 for Schwartz and 12-11 for Kaufman, and both are now likely to be confirmed by the Republican-controlled Senate.
The mechanics of one vote are worth dwelling on, because they reveal a recurring feature of how confirmation accountability actually works, and how weak it can be. Committee chair Bill Cassidy, a physician who had clashed with Kaufman over the nominee's past anti-vaccine statements, voted yes only after extracting private assurances from the Department of Health and Human Services. This is the second time in eighteen months that Cassidy has cast a decisive vote for a controversial HHS nominee in exchange for promises, and by STAT's reporting, the promises he secured the first time were not all kept. The pattern is the story, and it exposes a structural problem that has nothing to do with which party holds the votes.
What Cassidy traded for
Kaufman was the contested nominee. He has claimed without evidence that COVID-19 vaccines caused excessive death and injury, a claim contrary to the scientific evidence and to the assessment of health officials, who note the vaccines were tested in trials involving tens of thousands of people and are credited with saving millions of lives. He had also criticized the hepatitis B birth-dose vaccine and supported canceling mRNA vaccine funding. Because ASPR oversees the development of vaccines and medical countermeasures against pandemics, a nominee with those views for that job drew sharp scrutiny, and Cassidy's vote was genuinely in doubt.
What resolved it was a set of assurances. Cassidy said he agreed to back Kaufman after HHS officials, whom he did not name, agreed to unspecified personnel changes and to a restriction that the ASPR leader would not be involved in vaccine policy decisions or be the ultimate decision-maker on matters like mRNA. He acknowledged Kaufman had said irresponsible things about immunization, said the nominee had owned up to them privately, and summed up his reasoning with a phrase that captures the whole trade: you can't have perfection.
Why a vote-for-promise trade is structurally lopsided
Set aside the politics and look at the structure of the exchange, because it is the same regardless of party or nominee. A senator's confirmation vote and an official's promise are not symmetric things, and the asymmetry runs entirely in one direction.
A vote is a one-time, irreversible payment. Once Cassidy votes yes and the nominee is confirmed, the valuable thing he controlled, the confirmation, has been permanently transferred, and he cannot take it back. A promise, by contrast, is an ongoing obligation that the other side can revoke at any time, and there is no mechanism by which a senator can compel a confirmed official to honor a private assurance. The moment of maximum leverage is before the vote; after it, the senator has spent the only thing he had to trade and retains nothing to enforce the bargain except his own future displeasure, which is weak currency against an official already in office.
That asymmetry is compounded by the specific form of these promises. They were private rather than public, so there is no record to hold anyone to. They were unspecified, personnel changes and a vaguely bounded restriction, so compliance cannot even be clearly measured. And they were made by intermediaries, HHS officials Cassidy declined to name, rather than by the principal whose conduct is at issue. A private, vague, unenforceable commitment relayed through unnamed staff is close to the weakest possible instrument of accountability, and it is what a decisive vote was exchanged for.
The precedent that makes the repeat notable
None of this would be more than a general observation about confirmation politics if not for the precedent, which is what makes Thursday's vote genuinely puzzling rather than merely routine. Cassidy did essentially the same thing in February 2025, when he cast a pivotal vote to confirm Robert F. Kennedy Jr. as HHS secretary after relying on a set of assurances about how Kennedy would handle vaccine policy. According to STAT's reporting, Kennedy subsequently broke some of the promises he had apparently made to win Cassidy's support.
So the mechanism Cassidy is using has already been tested, with the same senator, the same department, and the same subject matter, and it reportedly failed. The assurances were given, the vote was cast, and the assurances were not fully honored. Repeating the identical approach with Kaufman, trusting new promises from the same department that reportedly did not keep the last ones, is the part that does not have an obvious explanation, and STAT notes plainly that it is not clear why Cassidy is choosing to extend that trust again. Whatever the reason, the structural lesson is hard to escape: if a promise-for-vote trade did not bind the department the first time, there is little reason to expect the second identical trade to bind it now, because nothing about the enforceability changed.
The oddity inside the promise itself
There is a further strangeness in the specific assurance that resolved Cassidy's concern, and it is worth naming because it is a tell. The promise was that Kaufman, if confirmed to lead ASPR, would be walled off from vaccine policy. But developing vaccines and countermeasures against pandemics is a central part of what ASPR does. The assurance therefore amounts to confirming someone to run an agency while carving out one of the agency's core functions from his authority.
That produces a dilemma with no comfortable resolution. Either the carve-out is real and enforceable, in which case ASPR would be led by someone formally excluded from a central piece of its mission, which raises the question of who exercises that authority instead and whether an agency can be coherently run by a head walled off from part of its own mandate. Or the carve-out is not truly enforceable, in which case it is a reassurance without substance, and the concern it was meant to address remains live. The very need for such a promise is a tell that the underlying worry, whether this nominee is suited to a role centrally involving vaccines, was never actually resolved. It was contracted around. A fitness concern serious enough to require walling the nominee off from part of his job is a concern the confirmation did not answer so much as paper over.
Both sides, fairly
The politics of whether to confirm these nominees is contested, and this analysis takes no position on it. But each side's case deserves its strongest statement, because the disagreement is real.
Cassidy's reasoning is defensible on its own terms. A senator works with the administration the country has, not the one he might prefer, and extracting even imperfect, hard-to-enforce commitments and carve-outs may be better than extracting nothing. Qualified nominees willing to serve are not unlimited, refusing every imperfect one can mean ceding an agency's leadership entirely or leaving it vacant during real public-health threats, and Cassidy pointed to genuine challenges, vaccine-preventable disease and an Ebola outbreak abroad, as reasons the posts need filling. "You can't have perfection" is a real governing philosophy, not merely an excuse, and reasonable people accept that confirmation is often a choice among flawed options.
The critics' case is equally grounded. Ranking member Bernie Sanders, who said he was impressed with Schwartz, opposed her anyway because he doubted she would stand up to Kennedy when it mattered, and the same logic applies more sharply to Kaufman. On this view, a confirmation vote is the one moment of real leverage the Senate holds over an executive-branch nominee, and spending it in exchange for private, unenforceable assurances, especially assurances of a kind that reportedly were not honored before, forfeits accountability rather than securing it. If the promises cannot be enforced, the argument goes, the vote should turn on the nominee's actual record, not on what officials pledge in private.
Both positions can be held in good faith, and which one persuades depends on how much weight a person puts on pragmatic realism versus enforceable accountability.
How to read it
The clean way to understand Thursday is that it was not really about two individuals but about a mechanism, and the mechanism is weaker than it looks. Conditioning a confirmation vote on future behavioral promises trades an enforceable power exercised now, the vote, for an unenforceable trust redeemed later, the promise, and once the vote is cast the leverage is gone. That trade can still be worth making if the promises are honored, but the track record in this exact relationship, the same senator and the same department, is that at least some were not, which is why repeating the approach invites the question STAT raised and did not answer.
For anyone following public-health leadership, the useful signal is to watch not the assurances but their enforcement, because assurances are what were offered and enforcement is what was missing last time. Whether Kaufman is in fact kept clear of vaccine policy, whether the unspecified personnel changes materialize, and whether the carve-out means anything in practice are the questions that will show whether this trade worked any better than the last one. The votes advanced the nominees; they did not resolve the concern that made the votes close, they relocated it into a set of promises whose enforceability is exactly what the last round called into doubt. A senator's vote is the strongest card he holds, and the recurring lesson here is that it is worth the most before it is played, and very little after.
Primary sources
- STAT for the committee's approval of Schwartz and Kaufman, the framing as a win for HHS Secretary Kennedy, Cassidy's explanation that he backed Kaufman after unnamed HHS officials agreed to unspecified personnel changes and a restriction that the ASPR leader not be involved in vaccine policy or be the ultimate decision-maker on mRNA, and the observation that Cassidy relied on similar HHS promises when supporting Kennedy in February 2025, some of which Kennedy subsequently broke.
- The Hill for the 12-10 Schwartz and 12-11 Kaufman committee votes, Cassidy's remarks that Kaufman "said some pretty stupid things" about immunization and had owned up to them, his "you can't have perfection" comment, and Sanders' statement that he opposed Schwartz because he doubted she would stand up to Kennedy.
- ABC News for Kaufman's past claim, made without evidence, that COVID-19 vaccines caused excessive death and injury, the contrary assessment of health officials citing large clinical trials and lives saved, and the scope of ASPR's responsibility for vaccine and countermeasure development.
- Axios for the postponed earlier vote, the depleted state of the administration's health leadership, Schwartz being the third CDC nominee following Susan Monarez, and Schwartz's hedge on whether she would tell Congress about pressure to adopt unscientific policies.
- NPR for Schwartz's confirmation-hearing statements about restoring trust through transparency and not betraying the science.
- Healio for the party-line committee tallies and the note that nominees need only a simple majority in the Republican-controlled Senate.